Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Morand-Joubert

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Transfusion|January 27, 1999
Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmissionJ J Lefrère, F Roudot-Thoraval, L Morand-Joubert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2021
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancersR Palich, M Veyri, A Vozy, et al.
The Journal of Antimicrobial Chemotherapy|December 5, 2013
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapyS Lambert-Niclot, C Charpentier, A Storto, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 31, 2016
Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtypeC Soulié, D B Fofana, N Boukli, et al.
Journal of Medical Virology|March 25, 2008
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutationC Delaugerre, P Flandre, A G Marcelin, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2018
Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West AfricaD B Fofana, M d'Almeida, S Lambert-Niclot, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2008
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavirB Masquelier, K L Assoumou, D Descamps, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 virusesS Lambert-Niclot, C Charpentier, A Storto, et al.
HIV Medicine|September 1, 2007
The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approachY Yazdanpanah, M Vray, J Meynard, et al.
The Journal of Antimicrobial Chemotherapy|December 14, 2011
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 studyM A Valantin, S Lambert-Niclot, P Flandre, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Transfusion|January 27, 1999
Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmissionJ J Lefrère, F Roudot-Thoraval, L Morand-Joubert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2021
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancersR Palich, M Veyri, A Vozy, et al.
The Journal of Antimicrobial Chemotherapy|December 5, 2013
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapyS Lambert-Niclot, C Charpentier, A Storto, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 31, 2016
Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtypeC Soulié, D B Fofana, N Boukli, et al.
Journal of Medical Virology|March 25, 2008
National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutationC Delaugerre, P Flandre, A G Marcelin, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2018
Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West AfricaD B Fofana, M d'Almeida, S Lambert-Niclot, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2008
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavirB Masquelier, K L Assoumou, D Descamps, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 virusesS Lambert-Niclot, C Charpentier, A Storto, et al.
HIV Medicine|September 1, 2007
The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approachY Yazdanpanah, M Vray, J Meynard, et al.
The Journal of Antimicrobial Chemotherapy|December 14, 2011
Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 studyM A Valantin, S Lambert-Niclot, P Flandre, et al.
Pageof 4